bioMérieux
A global leader in in vitro diagnostics for clinical and industrial applications.
BIM | PA
Overview
Corporate Details
- ISIN(s):
- FR0013280286 (+13 more)
- LEI:
- 549300AK8Y0LBIQ4T071
- Country:
- France
- Address:
- 376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
- Website:
- https://www.biomerieux.com/
- Sector:
- Manufacturing
Description
bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-06 11:20 |
Janvier 2025 - Déclaration sur le nombre d'actions composant le capital social …
|
French | PDF • 105.4 KB | ||
| 2025-01-13 07:15 |
bioMérieux to present at the 43rd Annual J.P. Morgan HealthCare Conference
|
English | PDF • 181.9 KB | ||
| 2025-01-13 07:15 |
bioMérieux présentera à la 43ème J.P. Morgan HealthCare Conference
|
French | PDF • 238.5 KB | ||
| 2025-01-13 07:00 |
bioMérieux strengthens its point of care presence with the acquisition of the i…
|
English | PDF • 321.7 KB | ||
| 2025-01-13 07:00 |
bioMérieux renforce sa présence sur le marché du diagnostic délocalisé (« Point…
|
French | PDF • 286.1 KB | ||
| 2025-01-07 12:31 |
Contrat de liquidité bioMérieux au titre du 2e semestre 2024
|
French | PDF • 248.2 KB | ||
| 2025-01-07 11:38 |
Décembre 2024 - Déclaration sur le nombre d'actions composant le capital social…
|
French | PDF • 106.1 KB | ||
| 2024-12-09 07:01 |
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes…
|
English | PDF • 270.9 KB | ||
| 2024-12-09 07:01 |
BIOFIRE® FILMARRAY® Tropical Fever Panel, un test PCR pour détecter l’origine d…
|
French | PDF • 281.8 KB | ||
| 2024-12-05 13:57 |
Novembre 2024 - Déclaration sur le nombre d'actions composant le capital social…
|
French | PDF • 105.8 KB | ||
| 2024-11-06 09:54 |
Octobre 2024 - Déclaration sur le nombre d'actions composant le capital social …
|
French | PDF • 105.3 KB | ||
| 2024-10-30 07:01 |
bioMérieux – Third-Quarter 2024 Business Review
|
English | PDF • 414.4 KB | ||
| 2024-10-30 07:01 |
bioMérieux – Information financière du 3ème trimestre 2024
|
French | PDF • 378.4 KB | ||
| 2024-10-15 07:01 |
bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to me…
|
English | PDF • 251.7 KB | ||
| 2024-10-15 07:01 |
bioMérieux obtient le marquage CE du test sanguin VIDAS® VITAMIN B12 TOTAL mesu…
|
French | PDF • 253.2 KB |
Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for bioMérieux
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for bioMérieux via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-04 | N/A | Other | Sell | 1,432 | 137,517.82 EUR |
| 2023-09-04 | N/A | Other | Sell | 1,253 | 120,328.10 EUR |
| 2023-09-01 | N/A | Other | Other | 2,900 | N/A |
| 2023-06-23 | N/A | Other | Other | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 300 | 23,193.00 EUR |
| 2023-06-23 | N/A | Other | Buy | 25 | 1,932.75 EUR |
| 2023-03-23 | N/A | Other | Sell | 16,500 | 1,650,415.80 EUR |
Peer Companies
